The estimated Net Worth of Bio Venture Partners Fund I... is at least $8.19 Milion dollars as of 1 August 2023. Bio I owns over 833,333 units of Inozyme Pharma stock worth over $8,188,771 and over the last 6 years Bio sold INZY stock worth over $0.
Sign up
Bio I INZY stock SEC Form 4 insiders trading
Bio has made over 4 trades of the Inozyme Pharma stock since 2018, according to the Form 4 filled with the SEC. Most recently Bio bought 833,333 units of INZY stock worth $3,999,998 on 1 August 2023.
The largest trade Bio's ever made was buying 1,070,000 units of Inozyme Pharma stock on 19 April 2022 worth over $3,948,300. On average, Bio trades about 607,139 units every 442 days since 2018. As of 1 August 2023 Bio still owns at least 1,571,741 units of Inozyme Pharma stock.
You can see the complete history of Bio I stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Bio I's mailing address?
Bio's mailing address filed with the SEC is 1700 Owens St, San Francisco, CA 94158, USA.
Insiders trading at Inozyme Pharma
Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.
What does Inozyme Pharma do?
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
What does Inozyme Pharma's logo look like?
Complete history of Bio I stock trades at Entasis Therapeutics Inc i Inozyme Pharma
Inozyme Pharma executives and stock owners
Inozyme Pharma executives and other stock owners filed with the SEC include:
-
Axel Bolte M.B.A., M.Sc.,
Co-Founder, Pres, CEO & Director -
Axel Bolte,
Co-Founder, Pres, CEO & Director -
Henric Bjorn Bjarke,
Sr. VP & COO -
Dr. David Thompson M.A., M.S., Ph.D.,
Chief Devel. Officer & Member of Scientific Advisory Board -
Gayle Gironda,
Sr. VP of HR -
Stefan Riley,
Director of Investor Relations -
Stephen J. DiPalma M.B.A.,
Interim Chief Financial Officer -
Dr. Kevin B. Johnson M.B.A., Ph.D., MBA.,
Sr. VP of Regulatory Affairs -
Dr. Pedro Huertas,
Sr. VP & Chief Medical Officer -
Dr. David Thompson Ph.D.,
Sr. Advisor -
Tara Greene,
VP of Quality & Compliance -
Brian Luque,
Director of Investor Relations -
Dr. Yves Sabbagh,
Sr. VP & Chief Scientific Officer -
Stephen Basso M.B.A.,
Sr. VP of Fin. -
Steven J. Jungles,
Sr. VP & Chief Technical Operations Officer -
Pharmaceuticals, Inc. Alexion,
10% owner -
Joseph Schlessinger,
10% owner -
Bio Venture Partners Fund I...,
-
Capital Partners Iii, Llc L...,
-
Enterprise Associates 15, L...,
-
Forest Baskett,
10% owner -
Mohamad Makhzoumi,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Steven J Jungles,
SVP, CTO -
Sanjay Subramanian,
SVP, CFO -
Douglas A Treco,
CEO -
Martin Edwards,
-
Sarah M Bhagat,
-
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Capital Management, L.P.Kol...,
-
Springs Capital Management ...,
-
Sanofi,
10% owner -
Holdings A/S Novo,
10% owner -
Lynne Marie Sullivan,
-
Reinaldo M Diaz,
-
Henric Bjorn Bjarke,
SVP, COO -
Edward T Mathers,
-
Venture Partners X, L.P.Sof...,
-
Joshua Makower,
10% owner -
Stephen Basso,
SVP Finance (PFO) -
Deborah Wenkert,
SVP, CMO -
Stephen J. Di Palma,
Interim CFO -
Pharma, Inc. Inozyme,
Director -
Axel Bolte,
-
Matthew Winton,
COO -
Robert Lorne Hopfner,